• Technical Name
  • BPRSJ338: Therapeutic Applications for COVID-19
  • Operator
  • National Health Research Institutes
  • Booth
  • Precision Health Ecosystem
  • Contact
  • 陳萲蓉
  • Email
  • enachen@nhri.edu.tw
Technical Description BPRSJ338 exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19 as a first-in-class drug. BPRSJ338 also potently inhibits against broad-spectrum coronaviruses including SARS-CoV-2, SARS-CoV, HCoV-229E, HCoV-OC43, TGEV, FIPV and MHV. Related US and Taiwan patents have been granted.​ Therefore it is also applicable to fight against severe evolving coronaviruses in the future.
Scientific Breakthrough BPRSJ338 is an inhibitor effectively against broad-spectrum coronaviruses. It exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19. BPRSJ338 targets the RNP complex containing viral RNA and nucleoprotein to block replication of coronaviruses including human coronavirus SARS-CoV, SARS-CoV-2, HCoV-229E, HCoV-OC43 as well as FIPV, TGEV and MHV. Related US and Taiwan patents have been granted. Strikingly, BPRSJ338​ exhibits a greater inhibitory activity (~50 to ~80 folds) against coronaviruses e.g. SARS-CoV-2, HCOV-OC43, than remdesivir .
Industrial Applicability Up to date, there is no effective vaccine or drug treatment for coronaviruses yet. BPRSJ338 exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19. BPRSJ338 also potently inhibits against broad-spectrum coronaviruses including SARS-CoV-2, SARS-CoV, HCoV-229E, HCoV-OC43, TGEV, FIPV and MHV. Therefore it is also applicable to fight against COVID-19 and other severe evolving coronaviruses in the future.
本網站使用您的Cookie於優化網站。繼續瀏覽網站即表示您同意本公司隱私權政策,您可至隱私權政策了解詳細資訊。